Clinical Trial Update: VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating VNP40101M in relapsed or refractory leukemia or myelodysplastic syndromes; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes

Drugs mentioned

• VNP40101M

Snippet

Sponsor: Vion Pharmaceuticals | Conditions: Leukemia, Myelodysplastic Syndromes | Phase 1 | Status: COMPLETED